# A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

> **NCT01506752** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Adult

## Interventions

- **DRUG:** Donepezil Hydrochloride
- **DRUG:** Donepezil Hydrochloride
- **DRUG:** Donepezil Hydrochloride
- **DRUG:** Donepezil Hydrochloride

## Key facts

- **NCT ID:** NCT01506752
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01506752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01506752, "A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01506752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*